Literature DB >> 10101720

Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.

V L Pereira-Chioccola1, F Costa, M Ribeirão, I S Soares, F Arena, S Schenkman, M M Rodrigues.   

Abstract

Immunization with naked DNA represents an attractive strategy for development of vaccines against a variety of infections including those caused by protozoan parasites. Recently, we have described that immunization with a plasmid containing the trans-sialidase (TS) gene induced protective immunity against Trypanosoma cruzi infection in BALB/c mice. The present study was aimed at examining and comparing the effectiveness of immunization using either plasmid or recombinant delivered antigens in a mouse strain highly susceptible to infection (A/Sn). Two plasmids were generated containing the coding region for the catalytic domain of TS. TS gene was inserted into pcDNA3 vector with or without the coding region for TS signal peptide. These two plasmids were found to be equally immunogenic at inducing antibodies to TS or inhibition of T. cruzi infection. A third plasmid, in which the TS gene was inserted into the vector VR1012, was as immunogenic as the two others. Immunization with a TS recombinant protein in alum generated a significantly higher antibody response as measured by ELISA or inhibition of TS enzymatic activity. Most relevant, this immunization reduced the mortality due to acute infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101720     DOI: 10.1046/j.1365-3024.1999.00201.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  13 in total

1.  Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.

Authors:  T A Pitcovsky; J Mucci; P Alvarez; M S Leguizamón; O Burrone; P M Alzari; O Campetella
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

3.  Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the Michaelis complex to the covalent intermediate.

Authors:  Gustavo Pierdominici-Sottile; Nicole A Horenstein; Adrian E Roitberg
Journal:  Biochemistry       Date:  2011-10-27       Impact factor: 3.162

4.  Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection.

Authors:  Valéria R A Pereira; Virginia M B Lorena; Mineo Nakazawa; Carlos F Luna; Edimilson D Silva; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Milena B P Soares; Eridan M Coutinho; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  Parasitol Res       Date:  2005-04-27       Impact factor: 2.289

5.  Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Authors:  O K Giddings; C S Eickhoff; T J Smith; L A Bryant; D F Hoft
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

6.  Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; John Sagartz; Daniel F Hoft
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

7.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.

Authors:  Christian Emerson Rosas-Jorquera; Luiz Roberto Sardinha; Fernando Delgado Pretel; André Luis Bombeiro; Maria Regina D'Império Lima; José Maria Alvarez
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

9.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

10.  Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis.

Authors:  Marcelo Sousa Silva; Duarte Miguel F Prazeres; Andreia Lança; Jorge Atouguia; Gabriel Amaro Monteiro
Journal:  Parasitol Res       Date:  2009-07-07       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.